Brief: Coya Therapeutics To Expand Pipeline For COYA 302 Further, Adding Alzheimer's Disease To List Of Indications Expected To Be Validated In Clinic
21/02/2024 13:27
Feb 21 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS - FURTHER EXPANDING PIPELINE FOR COYA
302,
ADDING ALZHEIMER'S DISEASE TO LIST OF INDICATIONS EXPECTED TO BE
VALIDATED IN CLINIC
Source text for Eikon: ID:nBw3cS9PPa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)